Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 8, 2012, Pages 680-693

  Askanas, Valerie ^a   Engel, W King ^a   Nogalska, Anna ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aging; Autophagy; Inclusion body myositis; Misfolded proteins; Multiprotein aggregates; Proteasome; Proteostasis

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CASEIN KINASE I; CYTOCHROME C OXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOCHONDRIAL DNA; OLIGOMER; POLYPHENOL; PROTEASOME; TAU PROTEIN;

AGING; AMINO TERMINAL SEQUENCE; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; HUMAN; INCLUSION BODY MYOSITIS; MITOCHONDRIAL DNA DEPLETION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

AGING; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AUTOPHAGY; BIOPSY; HUMANS; LITHIUM COMPOUNDS; MITOCHONDRIA, MUSCLE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PEPTIDE FRAGMENTS; PHENYLBUTYRATES; POLYPHENOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOSTASIS DEFICIENCIES; TAU PROTEINS;

EID: 84864434515     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31826183c8     Document Type: Review

References (127)

1. Engel WK, Askanas V. Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects. Neurology 2006;66:S20-29
2. Askanas V, Engel WK, Nogalska A. Pathogenesis of sporadic inclusionbody myositis; Role of ageing and muscle-fibre degeneration, and accumulation of the same proteins as in Alzheimer and Parkinson brains. In: Askanas V, Engel WK, eds. Muscle Ageing, Inclusion-Body Myositis and Myopathies. Oxford, UK: Wiley-Blackwell, 2012:111-45
3. Mastaglia F. Sporadic inclusion-body myositis: Clinical symptoms, physical findings, and diagnostic intvestigations. In: Askanas V, Engel WK, eds. Muscle Aging, Inclusion-Body Myositis and Myopathies. Oxford, UK: Wiley-Blackwell, 2012:159-67
4. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84
5. Dalakas MC. Inflammatory and autoimmune features of inclusion-body myositis. In: Askanas V, Engel WK, eds. Muscle Aging, Inclusion-Body Myositis and Myopathies. Oxford, UK: Wiley-Blackwell, 2012:146-58
6. Askanas V, Engel WK. Sporadic inclusion-body myositis: Conformational multifactorial ageingYrelated degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse Med 2011;40:219-35
7. Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66:S123-24
8. Amouri R, Driss A, Murayama K, et al. Allelic heterogeneity of GNE gene mutation in two Tunisian families with autosomal recessive inclusion body myopathy. Neuromuscul Disord 2005;15:361-63
9. Krause S, Schlotter-Weigel B, Walter MC, et al. A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. Neuromuscul Disord 2003;13:830-34
10. Askanas V, Engel WK. Inclusion-body myositis and myopathies: Different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 2002;15:525-31
11. Broccolini A, Mirabella M. Consequences of the hereditary inclusionbody myopathy-characteristic GNE mutations on muscle proteins in vivo and in vitro. In: Askanas V, Engel WK, eds. Muscle Ageing, Inclusion-Body Myositis and Myopathies. Oxford, UK: Wiley-Blackwell, 2012:199-205
12. Page LJ, Suk JY, Bazhenova L, et al. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci USA 2009;106: 11125-30
13. Askanas V, Engel WK. Inclusion-body myositis: Muscle fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008; 116:583-95
14. Askanas V, Engel WK. Inclusion-body myositis: A myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66:S39YS48
15. Morosetti R, Mirabella M, Gliubizzi C, et al. MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc Natl Acad Sci USA 2006;103: 16995-7000
16. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200
17. Engel WK, Cunningham GG. Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections. Neurology 1963;13:919-23
18. Askanas V, Engel WK, Alvarez RB. Enhanced detection of Congo-RedYpositive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 1993;43:1265-67
19. Askanas V, Engel WK. Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001;60:1-14
20. Vattemi G, Nogalska A, Engel WK, et al. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusionbody myositis. Acta Neuropathol 2009;117:569-74
21. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: A degenerative muscle disease associated with intra-muscle fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009;19:493-506
22. Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009;118:407-13
23. Bjorkoy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005;171:603-14
24. Seibenhener ML, Babu JR, Geetha T, et al. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004;24:8055-68
25. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008;79: 1186-89
26. Küsters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009; 117:209-11
27. Olivé M, Janué A, Moreno D, et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009;68:262-73
28. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009;40:19-31
29. D'Agostino C, Nogalska A, Engel WK, et al. In sporadic inclusion body myositis muscle fibres TDP-43Ypositive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol 2011;37:315-20
30. Balch WE, Morimoto RI, Dillin A, et al. Adapting proteostasis for disease intervention. Science 2008;319:916-19
31. Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol 2010;190:719-29
32. Sarkozi E, Askanas V, Johnson SA, et al. Beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993;4:815-18
33. Tanaka S, Shiojiri S, Takahashi Y, et al. Tissue-specific expression of three types of beta-protein precursor mRNA: Enhancement of protease inhibitorYharboring types in Alzheimer's disease brain. Biochem Biophys Res Commun 1989;165:1406-14
34. Terracciano C, Nogalska A, Engel WK, et al. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: Effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 2010;112:389-96
35. Vattemi G, Engel WK, McFerrin J, et al. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 2001;358:1962-64
36. Wojcik S, Engel WK, Yan R, et al. NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol 2007;114: 517-26
37. Sun X, Bromley-Brits K, Song W. Regulation of beta-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer's disease. J Neurochem 2012;120(Suppl 1):62-70
38. De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010;26:235-60
39. Nogalska A, Engel WK, Askanas V. Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibersVPossibly caused by endoplasmic reticulum stress. Neurosci Lett 2010;474:140-43
40. Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008;14:723-30
41. Askanas V, Alvarez RB, Engel WK. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993;34:551-60
42. Askanas V, Engel WK, Alvarez RB, et al. Beta-amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet 1992;339:560-61
43. Askanas V, Engel WK. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. Am J Pathol 1998;153:1673-77
44. Selkoe DJ. Aging, amyloid, and Alzheimer's diseas; A perspective in honor of Carl Cotman. Neurochem Res 2003;28:1705-13
45. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509
46. Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem 2012;120(Suppl 1):125-39
47. Masuda Y, Uemura S, Ohashi R, et al. Identification of physiological and toxic conformations in Abeta42 aggregates. Chembiochem 2009; 10:287-95
48. Nogalska A, D'Agostino C, Engel WK, et al. Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 2010;120:661-66
49. Abdo WF, van Mierlo T, Hengstman GJ, et al. Increased plasma amyloidbeta42 protein in sporadic inclusion body myositis. Acta Neuropathol 2009;118:429-31
50. Klein WL, Stine WB Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004;25:569-80
51. Engel WK, Trotter JL. Plasma-cell dyscrasic amyloid neuropathy: A parasparafucile phenomenon? In: Serratrice G, Roux H, eds. Peroneal Atrophies and Related Disorders. New York, NY: Masson Publishing Co., 1979:333-38
52. Honson NS, Kuret J. Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis 2008;14:417-22
53. Iqbal K, Liu F, Gong CX, et al. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118:53-69
54. Mirabella M, Alvarez RB, Bilak M, et al. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996;55:774-86
55. Jicha GA, Lane E, Vincent I, et al. A conformation-and phosphorylationdependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem 1997;69:2087-95
56. Iqbal K, Wang X, Blanchard J, et al. Alzheimer's disease neurofibrillary degeneration: Pivotal and multifactorial. Biochem Soc Trans 2010;38: 962-66
57. Wilczynski GM, Engel WK, Askanas V. Association of active extracellular signalYregulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation. Am J Pathol 2000;156:1835-40
58. Wilczynski GM, Engel WK, Askanas V. Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation. Neurosci Lett 2000;293:33-6
59. Kannanayakal TJ, Mendell JR, Kuret J. Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett 2008;431:141-45
60. Martinez A, Portero-Otin M, Pamplona R, et al. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010;20:281-97
61. Terracciano C, Nogalska A, Engel WK, et al. In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med 2008;45:773-79
62. Yang CC, Alvarez RB, Engel WK, et al. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 1996; 8:153-58
63. Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrit; Implications for Alzheimer's disease. Biochemistry 2005;44:1690-700
64. Zhang YJ, Xu YF, Chen XQ, et al. Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. FEBS Lett 2005;579:2421-27
65. Crews L, Tsigelny I, Hashimoto M, et al. Role of synucleins in Alzheimer's disease. Neurotox Res 2009;16:306-17
66. Devine MJ, Gwinn K, Singleton A, et al. Parkinson's disease and alpha-synuclein expression. Mov Disord 2011;26:2160-68
67. Vekrellis K, Xilouri M, Emmanouilidou E, et al. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011;10: 1015-25
68. Askanas V, Engel WK, Alvarez RB, et al. Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 2000;59:592-98
69. Paciello O, Wojcik S, Engel WK, et al. Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPPoverexpressing cultured human muscle fibers. Acta Myol 2006;25: 13-22
70. Sridhar S, Botbol Y, Macian F, et al. Autophagy and disease; Always two sides to a problem. J Pathol 2012;226:255-73
71. Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 2010;5:e9313
72. Devi L, Anandatheerthavarada HK. Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 2010; 1802:11-19
73. Kawakami F, Suzuki M, Shimada N, et al. Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J 2011; 278:4895-904
74. Engel WK. "Ragged-red fibers" in opthamoplegia syndromes and their differential diagnosis. Excerpta Med Inter Cong Series 1971;237;28
75. Oldfors A, Moslemi AR, Jonasson L, et al. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006;66:S49-55
76. Narendra D, Tanaka A, Suen DF, et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183:795-803
77. Batlevi Y, La Spada AR. Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis 2011;43:46-51
78. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-59
79. Choi J, Sullards MC, Olzmann JA, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 2006;281:0816-24
80. Taira T, Saito Y, Niki T, et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004;5:213-18
81. Ciechanover A. The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006;66:S7-19
82. Li XJ, Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol Dis 2011;43:4-8
83. Nixon RA, Yang DS. Autophagy failure in Alzheimer's diseaseV Locating the primary defect. Neurobiol Dis 2011;43:38-45
84. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008;12:363-73
85. Fratta P, Engel WK, McFerrin J, et al. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in AAPP-overexpressing cultured human muscle fibers. Am J Pathol 2005; 167:517-26
86. Ferrer I, Mart'n B, Castaño JG, et al. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004;63:484-98
87. Fratta P, Engel WK, Van Leeuwen FW, et al. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 2004;63:1114-17
88. Keck S, Nitsch R, Grune T, et al. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003;85:115-22
89. Lindersson E, Beedholm R, Hojrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004;279:12924-34
90. Dennissen FJA, Kholod N, Steinbusch HWM, et al. Misframed proteins and neurodegeneration: A novel view on Alzheimer's and Parkinson's diseases. Neurodegenerative Dis 2010;7:76-79
91. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009;118:329-47
92. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009;43:67-93
93. Carpenter S, Karpati G, Heller I, et al. Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28:8-17
94. Nogalska A, D'Agostino C, Terracciano C, et al. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stressY provoked cultured human muscle fibers. Am J Pathol 2010;177:1377-87
95. Hamano T, Gendron TF, Causevic E, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wildtype tau expression. Eur J Neurosci 2008;27:1119-30
96. Mueller-Steiner S, Zhou Y, Arai H, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer's disease. Neuron 2006;51:703-14
97. Yu WH, Cuervo AM, Kumar A, et al. MacroautophagyVA novel beta-amyloid peptideYgenerating pathway activated in Alzheimer's disease. J Cell Biol 2005;171:87-98
98. Kirkin V, Lamark T, Sou YS, et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol Cell 2009;33:505-16
99. D'Agostino C, Nogalska A, Cacciottolo M, et al. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol 2011;122:627-36
100. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001;12:2085-90
101. Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease; Possible role in tangle formation. Neuropathol App Neurobiol 2002;28:228-37
102. Fukuchi K, Pham D, Hart M, et al. Amyloid-beta deposition in skeletal muscle of transgenic mice; Possible model of inclusion body myopathy. Am J Pathol 1998;153:1687-93
103. Jin LW, Hearn MG, Ogburn CE, et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998;153:1679-86
104. Kitazawa M, Green KN, Caccamo A, et al. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositislike pathology and motor deficits in transgenic mice. Am J Pathol 2006; 168:1986-97
105. Moussa CE-H, Fu Q, Kumar P, et al. Transgenic expression of A-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBMlike pathology. FASEB J 2006;20:2165-67
106. Lopez JR, Shtifman A. Intracellular A-amyloid accumulation leads to age-dependent progression of Ca2+ dysregulation in skeletal muscle. Muscle Nerve 2010;42:731-38
107. Shtifman A, Ward CW, Laver DR, et al. Amyloid-A protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol Aging 2010; 31:2080-90
108. Masiero E, Agatea L, Mammucari C, et al. Autophagy is required to maintain muscle mass. Cell Metab 2009;10:507-15
109. Askanas V, McFerrin J, Baque S, et al. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996;93:1314-19
110. Askanas V, McFerrin J, Alvarez RB, et al. Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997;8:2155-58
111. McFerrin J, Engel WK, Askanas V. Impaired innervation of cultured human muscle overexpressing betaAPP experimentally and genetically: Relevance to inclusion-body myopathies. Neuroreport 1998;9: 3201-5
112. McFerrin J, Engel WK, Leclerc N, et al. Combined influence of amyloidbeta precursor protein (AbPP) gene transfer and cholesterol excess on cultured humen muscle fibers abstract. Neurology 2002;58:489
113. Wojcik S, Nogalska A, McFerrin J, et al. Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusionbody myositis culture model. Neuropathol Appl Neurobiol 2007;33: 238-42
114. Wojcik S, Engel WK, McFerrin J, et al. AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscl; relevance to inclusion-body myositis. Neuromuscul Disord 2006;16:839-44
115. Alvarez RB, Engel W, Askanas V. Ultrastructural abnormalities of neuromuscular juunctions in sporadic inclusion-body myositis abstract. Neurology 2000;54(Suppl 3):240-41
116. Nogalska A, D'Agostino C, Engel WK, et al. Experimental impairment of the autophagosomal-lysosomal pathway (ALP) in our cultured human-muscle-fibers model of s-IBM (IBM-CHMFs Model) activates F-secretase, resulting in adversely increased production of amyloid-A 42 (AA42) and its subsequent detrimental oligomerization. Relevance to sporadic inclusion-body myositis (s-IBM) pathogenesis abstract. Neurology 2011;76:106
117. Nogalska A, D'Agostino C, Engel WK, et al. Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis muscle fibers. Neurobiol Aging 2010;31:1637-48
118. Nogalska A, Wojcik S, Engel WK, et al. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 2007; 204:610-18
119. Nogalska A, Engel WK, McFerrin J, et al. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stressYinduced cultured human muscle fibers. J Neurochem 2006;96:1491-99
120. Engel T, Goni-Oliver P, Gomez de Barreda E, et al. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 2008;5: 247-49
121. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008;64:15-24
122. Cucciolla V, Borriello A, Oliva A, et al. Resveratrol: From basic science to the clinic. Cell Cycle 2007;6:2495-510
123. Nogalska A, D'Agostino C, Engel WK, et al. Resveratrol, a polyphenol found in red wine, reduces NF-JB activation and myostatin in endoplasmic reticulum stress (ERS)Yprovoked cultured human muscle fibers: Relevance to treatment of sporadic inclusion-body myositis. (Abstract) Ann Neurol 2008;64:S9
124. Hamaguchi T, Ono K, Murase A, et al. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 2009;175:2557-65
125. Papp E, Csermely P. Chemical chaperones: Mechanisms of action and potential use. Handb Exp Pharmacol 2006;405-16
126. Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009;10: 99-106
127. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington's disease; A dose-finding study. Mov Disord 2007;22:1962-64